VEGFA and neoplasm: The oral dose of GW654652 producing 50% inhibition of tumour growth (ED50) decreased with increasing levels of VEGF (r=−0.94); and, in contrast, the ED50 increased with the increased expression of VEGFR2 (r=0.82).